Calliditas IgAN Pocket Guide

Intended for US Healthcare professionals. KDIIGA05223b 5/22 US-CALT-2200036 Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It is applicable to specialists, primary care, and providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Abbreviations ACEi, angiotensin-converting enzyme inhibitor; AKI, acute kidney injury; ARB, angiotensin II receptor blocker; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GN, glomerulonephritis; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgAN, immunoglobulin A nephropathy; MEST-C, mesangial (M) and endocapillary (E) hypercellularity/ segmental sclerosis (S)/ interstitial fibrosis/tubular atrophy (T)/ and crescents (C); MCD, minimal-change disease; RCT, randomized controlled trial; RPGN, rapidly progressive glomerulonephritis; TESTING, erapeutic Evaluation of Steroids in IgA Nephropathy Global; TB, tuberculosis Implications Grade Patients Clinicians Policy Level 1 "We recommend" Most people in your situation would want the recommended course of action, and only a small proportion would not. Most patients should receive the recommended course of action. e recommendation can be evaluated as a candidate for developing a policy or a performance measure. Level 2 "We suggest" e majority of people in your situation would want the recommended course of action, but many would not. Different choices will be appropriate for different patients. Each patient needs help to arrive at a management decision consistent with her or his values and preferences. e recommendation is likely to require substantial debate and involvement of stakeholders before policy can be determined. Grade Quality of Evidence Meaning A High We are confident that the true effect is close to the estimate of the effect. B Moderate e true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. C Low e true effect may be substantially different from the estimate of the effect. D Very low e estimate of effect is very uncertain, and oen it will be far from the true effect.

• Cover